Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badania przesiewowe w kierunku raka jajnika u starszych pacjentek (badanie przesiewowe PLCO)

10 listopada 2026 zaktualizowane przez: National Cancer Institute (NCI)

Próba przesiewowa raka prostaty, płuc, jelita grubego i jajnika (PLCO).

This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for ovarian cancer. The ovarian cancer screening tests are part of a trial that addresses the screening of four cancer sites, each with their own results record: prostate (NCT00002540), lung (NCT01696968), colorectal (NCT01696981), and ovarian (NCT01696994).

Przegląd badań

Status

Aktywny, nie rekrutujący

Warunki

Interwencja / Leczenie

Szczegółowy opis

PRIMARY OBJECTIVES:

I. To determine whether screening with CA125 and transvaginal ultrasound (TVU) can reduce mortality from ovarian cancer in women aged 55-74 at entry.

SECONDARY OBJECTIVES:

I. To assess screening variables, other than mortality, for each of the interventions including sensitivity, specificity, and positive predictive value.

II. To assess the incidence, stage, and survival of cancer cases. III. To investigate the mortality predictive value of biologic and/or prognostic characterizations of tumor tissue as intermediate endpoints.

IV. To conduct biomolecular and genetic research into factors associated with cancer carcinogenesis and promotion, as well as the early detection of these factors.

OUTLINE: Participants in the overall PLCO study are stratified by screening center, gender, and age (55-59 vs 60-64 vs 65-69 vs 70-74). Participants are randomized to 1 of 2 arms (control vs screening).

ARM I (Control): Participants receive standard medical care. Participants complete a Diet History Questionnaire (DHQ) at baseline.

ARM II (Ovarian Screening): Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an ovarian palpation exam (OVR, discontinued in December 1998) and TVU at baseline and annually for 3 years. A scheduling and tracking procedure is implemented to ensure regular attendance at repeat screens for participants screened negative or for those who are designated suspicious or positive at screening but for whom subsequent diagnostic procedures do not reveal ovarian cancer (follow-up diagnostic procedures are through their own medical care environment). Participants diagnosed with ovarian cancer via a screening test are referred for treatment in accordance with current accepted practice for appropriate stage of disease, patient age, and medical condition; a procedure is provided for contact with qualified medical personnel to insure appropriate therapy.

Participants complete a Dietary Questionnaire (DQX) at baseline and DHQ at year 3. An Annual Study Update (ADU) (previously referred to as the Periodic Survey of Health [PSH] questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial.

After completion of screening, participants are followed up for at least 13 years.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

78216

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Maryland
      • Bethesda, Maryland, Stany Zjednoczone, 20892
        • National Institutes of Health Clinical Center

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

55 lat do 74 lata (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Kobieta

Opis

Exclusion Criteria:

  • Women who at the time of randomization are less than 55 or greater than or equal to 75 years of age

  • Individuals undergoing treatment for cancer at this time, excluding basal-cell and squamous-cell skin cancer

  • Individuals with known prior cancer of the colon, rectum, lung, or ovary

    • This includes primary or metastatic PLCO cancers
  • Individuals with previous surgical removal of the entire colon or one lung

    • Until October 1996, women with previous surgical removal of both ovaries were excluded from the trial. In order to increase the enrollment of women into the trial, beginning in October 1996, these women were no longer excluded for this reason.
  • Individuals who are participating in another cancer screening or cancer primary prevention trial

  • Prior to April 1, 1999 women were excluded from the trial if they were currently taking or had taken Tamoxifen or Evista\Raloxifene in the past 6 months. As of April 1999 based on a decision from the PLCO Ovary Subcommittee, women who have or are currently taking Tamoxifen or Evista\Raloxifene are not excluded from participation.

  • Individuals who are unwilling or unable to sign the informed consent form

  • Individuals who have had a colonoscopy, sigmoidoscopy, or barium enema in the past three years

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Ekranizacja
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Pojedynczy

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Brak interwencji: Control

Participants receive standard medical care. Participants complete a DHQ at baseline.

Aktywny komparator: Ovarian Screening

Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial.

Correlative studies

Undergo questionnaire assessments

Undergo TVU

Inne nazwy:
  • Ultradźwięk
  • Dwuwymiarowe obrazowanie ultrasonograficzne w skali szarości
  • Dwuwymiarowe obrazowanie ultrasonograficzne
  • 2D-USA
  • Badanie ultrasonograficzne
  • USG, medyczne
  • NAS
  • Ultrasonografia

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Ovarian Cancer Deaths (Including Primary Peritoneal and Fallopian Tube Cancers)
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Ovarian cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Ovarian Cancer Death Rates (Including Primary Peritoneal and Fallopian Tube Cancers)
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Ovarian cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Deaths From All Causes
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Deaths from all causes were compared between the ovarian cancer screening arm and the usual care arm.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Death Rates From All Causes
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Deaths from all causes were compared between the ovarian cancer screening arm and the usual care arm. Rate is the number of deaths divided by person years of follow-up in the study.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Ovarian Cancer Incidence (Including Primary Peritoneal and Fallopian Tube Cancers)
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Ovarian cancer diagnoses confirmed by medical record abstraction.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Ovarian Cancer Incidence Rates (Including Primary Peritoneal and Fallopian Tube Cancers).
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Ovarian cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as ovarian cancer diagnoses divided by person years at risk for ovarian cancer.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test
Ramy czasowe: One year from screening examination

Number of positive screens with complications

One year from screening examination
T0 (Baseline) CA-125 Screening Results
Ramy czasowe: T0 (at study entry)

Cancer Antigen 125 (CA-125) result.

T0 (at study entry)
T0 (Baseline) TVU Screening Results
Ramy czasowe: T0 (at study entry)

Transvaginal Ultrasound (TVU) result.

T0 (at study entry)
T1 CA-125 Screening Results
Ramy czasowe: T1 (one year after entry)

Cancer Antigen 125 (CA-125) result.

T1 (one year after entry)
T1 TVU Screening Results
Ramy czasowe: T1 (one year after entry)

Transvaginal Ultrasound (TVU) result.

T1 (one year after entry)
T2 CA-125 Screening Results
Ramy czasowe: T2 (two years after entry)

Cancer Antigen 125 (CA-125) result.

T2 (two years after entry)
T2 TVU Screening Results
Ramy czasowe: T2 (one year after entry)

Transvaginal Ultrasound (TVU) result.

T2 (one year after entry)
T3 CA-125 Screening Results
Ramy czasowe: T3 (three years after entry)

Cancer Antigen 125 (CA-125) result.

T3 (three years after entry)
T3 TVU Screening Results
Ramy czasowe: T3 (three years after entry)

Transvaginal Ultrasound (TVU) result.

T3 (three years after entry)
T4 CA-125 Screening Results
Ramy czasowe: T4 (four years after entry)

Cancer Antigen 125 (CA-125) result.

T4 (four years after entry)
T5 CA-125 Screening Results
Ramy czasowe: T5 (five years after entry)

Cancer Antigen 125 (CA-125) result.

T5 (five years after entry)

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Główny śledczy: Christine D Berg, National Cancer Institute (NCI)

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

16 listopada 1993

Zakończenie podstawowe (Rzeczywisty)

21 maja 2012

Ukończenie studiów (Szacowany)

30 czerwca 2027

Daty rejestracji na studia

Pierwszy przesłany

28 września 2012

Pierwszy przesłany, który spełnia kryteria kontroli jakości

1 października 2012

Pierwszy wysłany (Szacowany)

2 października 2012

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

13 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

10 listopada 2026

Ostatnia weryfikacja

1 lipca 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • NCI-2012-01758
  • CDR0000078532
  • NCI-P93-0050
  • PLCO-1
  • NCI-2012-01758 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
  • PLCO-Ovarian (Inny identyfikator: National Cancer Institute)

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .